This STAT3-Treg axis disruption reverses TME immunosuppression, enabling GA to potentiate anti-PD-1 therapy in CRC models by boosting IFN-γ+ CD8+ T cell infiltration and attenuating PD-1/PD-L1 signaling (130). The gene discussed is IFNG; the disease is colorectal carcinoma.